Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Significant Growth in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 123,500 shares, an increase of 21.7% from the August 15th total of 101,500 shares. Approximately 8.3% of the shares of the stock are sold short. Based on an average trading volume of 679,800 shares, the short-interest ratio is presently 0.2 days. Based on an average trading volume of 679,800 shares, the short-interest ratio is presently 0.2 days. Approximately 8.3% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded Avalon GloboCare to a “strong sell” rating in a report on Saturday, September 13th.

Avalon GloboCare Stock Performance

NASDAQ ALBT opened at $2.69 on Friday. Avalon GloboCare has a twelve month low of $1.87 and a twelve month high of $11.66. The stock has a market capitalization of $10.33 million, a PE ratio of -0.13 and a beta of 0.02. The stock has a 50-day simple moving average of $2.32 and a 200 day simple moving average of $3.41.

Avalon GloboCare (NASDAQ:ALBT) last released its quarterly earnings data on Thursday, August 14th. The company reported ($2.02) earnings per share for the quarter. The firm had revenue of $0.35 million during the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.